Compare NATR & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NATR | AURA |
|---|---|---|
| Founded | 1972 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 470.3M | 333.4M |
| IPO Year | 1995 | 2021 |
| Metric | NATR | AURA |
|---|---|---|
| Price | $25.10 | $5.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $21.33 | $20.20 |
| AVG Volume (30 Days) | 101.0K | ★ 206.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.33 |
| EPS | ★ 0.83 | N/A |
| Revenue | ★ $454,364,000.00 | N/A |
| Revenue This Year | $7.30 | N/A |
| Revenue Next Year | $3.44 | N/A |
| P/E Ratio | $31.22 | ★ N/A |
| Revenue Growth | ★ 2.03 | N/A |
| 52 Week Low | $11.01 | $4.73 |
| 52 Week High | $28.14 | $7.73 |
| Indicator | NATR | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 40.53 | 47.37 |
| Support Level | $13.69 | $5.08 |
| Resistance Level | $26.96 | $6.12 |
| Average True Range (ATR) | 0.96 | 0.42 |
| MACD | -0.32 | 0.01 |
| Stochastic Oscillator | 10.34 | 48.63 |
Natures Sunshine Products Inc is a natural health and wellness company, predominantly engaged in the manufacturing and selling of nutritional and personal care products. It offers products related to Weight management, General health, Cardiovascular, Digestive, Immune, and Personal care. The company operates in four segments namely, Asia which is also its key revenue generating market, Europe, North America, Latin America, and Other.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.